Morning Health Learning Center - What is Zepbound(tirzepatide)? Lilly's Newly Approved Medication for Chronic Weight Management

Credit to

views

On Nov. 8, 2023, The U.S. Food and Drug Administration (FDA) approved Eli Lilly and Company's (NYSE: LLY) Zepbound™ (tirzepatide) injection, the first and only obesity treatment of its kind that activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) hormone receptors.

‍

What's the difference between Zepbound and Mounjaro?

Mounjaro is for diabetes, and Zepbound is approved for weight loss. They are both tirzepatide

‍

Clinical Trial Results: average 48 lb. weight loss at the highest dose

In SURMOUNT-1, a study in 2,539 adults with obesity, or excess weight and weight-related medical problems not including diabetes, people taking Zepbound as an adjunct to diet and exercise experienced substantial weight loss compared with placebo at 72 weeks. At the highest dose (15 mg), people taking Zepbound lost on average 48 lb., while at the lowest dose (5 mg), people lost on average 34 lb. (compared to 7 lb. on placebo). The average starting weight was 231 lb.

‍

When is Zepbound available?‍

Zepbound is expected to be available in the U.S. by the end of the year (2023) in six doses (2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg).

‍

How much does Zepbound cost?‍

List price: $1,059.87, approximately 20% lower than semaglutide 2.4 mg injection for weight loss.
Savings card program:
1). As low as $25 for a 1-month or 3-month prescription, if you are commercially insured with coverage for Zepbound.
2). As low as $563 for a 1-month prescription, if you are commercially insured without coverage for Zepbound.
The savings card program at: https://www.zepbound.lilly.com/

‍

Your Cart

What is Zepbound(tirzepatide)? Lilly's Newly Approved Medication for Chronic Weight Management

Contact

Quick Links

Company

What is Zepbound(tirzepatide)? Lilly's Newly Approved Medication for Chronic Weight Management

Subscribe Newsletter

Contact

Quick Links

Company